Benefit/risk analysis
News
+ Info sheets
Agenda
Benefit/risk analyses of products containing nanos
By the AVICENN team – Last modification in April 2022
The benefit/risk analysis of products containing nanos must cover the whole life cycle of the products and integrate the impacts for all involved… especially the most vulnerable.
It is not only the health and environmental risks associated with nanomaterials that need to be carefully assessed.
The benefits of nanos also need to be seriously examined and evaluated.
For each type of product, the following questions arise:
- What needs are nanomaterials supposed to meet?
- What functions do they perform? Are they essential? Useful or futile? Who benefits (manufacturers / distributors / users)?
- What evidence is there of the benefits described? Are they provided in understandable language? On a sales pitch or on a safety data sheet?
- Do these pieces of information describe noticeable, perceptible and important benefits to you?
- How are decisions made: who decides what, at what point in the innovation life cycle? Which stakeholders are impacted at each stage of the innovation life cycle? Have they been able to express an opinion and is it taken into account?
- Is the use of nanomaterials limited, reserved for a confined professional environment?
- Will the health, environmental and social impacts be significantly altered by a commercial extension to the general public?
- Have the consequences of a generalization of these products integrating nanomaterials / nanotechnologies been simulated?
- Have waste flow simulations been done?
- Do alternatives exist? and are they more or less “effective” than the advertised properties related to “added nanos”?
Elsewhere on the web
In French :
- Ecological transition in research: greener chemistry for a sustainable world, Pierre Lalanne, La Recherche, 28 March 2022
In English:
-
Forget microplastics: we may have a much smaller problem, The Guardian, 25 April 2022
Any questions or comments? This information sheet compiled by AVICENN is intended to be completed and updated. Please feel free to contribute.
Other news on the topic
Our information sheets to go further
Upcoming Nano Agenda
27
Jan.
2026
Nanotechnologies and agriculture: a reference framework for responsible practice (AFNOR, online)
On line
Webinar
- Webconference for analysis laboratories, plant fertilizer manufacturers and distributors, public authorities…
- Moderated by David Krupka, nanotechnologies development manager at AFNOR Normalisation and Emilie Langlois-Bertrand, nantechnologies standardization project manager.
- In partnership with Armand Masion, CNRS Research Director, and Sandrine Mocoeur, Health, Safety, Environment and Quality Manager at SYNGENTA.
- This exchange will also be an opportunity to explore the creation of a national platform to identify standardization needs.
- Website: www.afnor.org/evenement/nanotechnologies-agriculture-cadre-pratique-responsable/
2
Juin
2026
Emerging pathologies and risks (CNMST 2026, Lyon – France)
Lyon
Congress
- 8th Congress of Occupational Medicine and Health (CNMST 2026)
- Theme 5: Emerging pathologies and risks, Mr Henri Bastos (ANSES), Pr Lynda Bensefa-Colas (AP-HP), Dr Catherine Nisse (CHU Lille)
- Website: www.medecine-sante-travail.com
26
Juin
2026
Nanomaterials and Health (ANSES, Maisons-Alfort)
Maisons-Alfort
Dialogue Committee
- 20th meeting of the “nano and health” dialogue committee
- Organizer: ANSES
File initially put on line in October 2013